EZH2 and small cell lung carcinoma: Consequently, the promotion of senescence by SAHA and the suppression of SASP by EZH2 inhibition weakens the progression and relapse of tumors and may provide a therapeutic strategy to improve the treatment effects of SAHA in SCLC.